Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever

1 Jul 2022

Abstract excerpt

Lassa virus (LASV) is recognized by the World Health Organization as one of the top five pathogens likely to cause a severe outbreak. A recent unprecedented resurgence of LASV in Nigeria caused by genetically diverse strains underscores the need for licensed medical countermeasures. Single-injection vaccines that can rapidly control outbreaks and confer long-term immunity are needed. Vaccination of cynomolgus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Viral Infections and Outbreaks Research
Share to Viral Infections and Vectors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35858566
DOI: 10.1016/j.celrep.2022.111094

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa feverPMID 35858566Read ↗

A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.Semantic proximity Read ↗

Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shotSemantic proximity Read ↗

Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteinsSemantic proximity Read ↗

A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strainsSemantic proximity Read ↗

Baseline mapping of Lassa fever virology, epidemiology and vaccine research and developmentSemantic proximity Read ↗

Lassa virus diversity and feasibility for universal prophylactic vaccineSemantic proximity Read ↗

Immunogenicity and Safety of Recombinant Rabies Viruses Used for Oral Vaccination of Stray Dogs and WildlifeSemantic proximity Read ↗

A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigsSemantic proximity Read ↗

A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous GlycoproteinsSemantic proximity Read ↗

A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virusSemantic proximity Read ↗

Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeysSemantic proximity Read ↗

General Molecular Strategy for Development of Arenavirus Live-Attenuated VaccinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.